Cogent Biosciences (COGT) vs Immunome (IMNM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cogent Biosciences (COGT) has outperformed Immunome (IMNM) over the past year, gaining 93.1% versus a gain of 37.8%. Over five years, COGT leads with a +225.5% price change compared with +9.7% for IMNM. Cogent Biosciences is the larger company by market cap ($5.31 billion vs $2.32 billion), about 2.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COGT | IMNM |
|---|---|---|
| Share price | $30.63 | $19.67 |
| Market cap | $5.31B | $2.32B |
| 1-day change | +1.81% | +1.86% |
| YTD return | -15.32% | -10.10% |
| 1-year return | +93.07% | +37.83% |
| 5-year return | +225.54% | +9.65% |
| EPS (TTM) | $-2.16 | $-2.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $6.94M |
| Revenue growth (YoY) | — | -23.23% |
| Net income (latest FY) | $-328.94M | $-212.39M |
| Operating margin | — | -3228.83% |
| Net margin | — | -3059.99% |
| 52-week high | $43.73 | $30.06 |
| 52-week low | $13.78 | $13.49 |
| Distance from 52-week high | -29.97% | -34.56% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +82.27% | +78.95% |
| Average volume | 1.90M | 1.20M |
| Shares outstanding | 173.52M | 118.00M |
| Employees | 258 | 247 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Cogent Biosciences is about 2.3 times larger than Immunome by market value ($5.31B vs $2.32B).
- COGT has outperformed IMNM by 55.2 percentage points over the past year.
About Cogent Biosciences
COGT stock →Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 247 employees
COGT vs IMNM FAQ
Which is bigger, Cogent Biosciences or Immunome?
Cogent Biosciences (COGT) is larger, with a market capitalization of $5.31B compared with $2.32B for Immunome (IMNM).
Which stock has performed better over the past year, COGT or IMNM?
COGT returned +93.07% over the past 12 months, compared with +37.83% for IMNM (price return, excluding dividends). Past performance does not predict future results.
Are Cogent Biosciences and Immunome in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.